Amgen announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with Remicade (infliximab) in patients with moderate-to-severe rheumatoid arthritis.
Innoplexus CEO Gunjan Bhardwaj responded to questions from Med Ad News about his company’s study of consumer perceptions of the pharma industry.
The EC approved Herzuma for patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have HER2 overexpression or HER2 gene amplification.
The American College of Rheumatology published a new white paper, “The Science Behind Biosimilars – Entering a New Era of Biologic Therapy,” providing a comprehensive overview of the scientific, clinical, economic and prescribing issues pertaining to biosimilar use, including efficacy, competition and drug pricing.
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.
Samsung Bioepis Co. Ltd. announced the European Commission’s marketing authorization of Ontruzant – a biosimilar referencing Herceptin (trastuzumab) – for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
ZS oncology experts Christina Corridon and Pavan Anne discuss their recent survey of physicians, payers, and pharmacy managers regarding attitudes toward biosimilars
Most health plans are covering at least one of the two biosimilar products currently on the market, according to new research by the strategic advisory company Avalere.
Four in five oncologists have tried Zarxio/Granix, according to a new survey by ZS Associates. Of those, 48 percent prescribe the reference biologic more than the biosimilar, 43 percent prescribe the biosimilar more, and 8 percent have equal prescriptions for the reference biologic and the biosimilar.